Pfizer Inc Pfizer Near-Term Launches + High-Value Pipeline Day Call
Simply, we’re just not the same company we were a few short years ago. We went from delivering $40-plus billion in revenue to one that is expected to reach between $99 billion to $102 billion. Those are the figures that we’ve given you at Q3 earnings. So that’s kind of more than doubling our revenue in 2 short years. I’m
DECEMBER 12, 2022 / 6:00PM, PFE.N – Pfizer Inc Pfizer Near-Term Launches + High-Value Pipeline Day Call The DMC noted that the vaccine was well tolerated with no safety concerns for vaccinated individuals. And again, I want to emphasize that our investigational vaccine does not have any adjuvant or viral vector component. Before going over the Phase III interim study results on maternal indication, I would like to underline Pfizer’s pioneering approach in RSV prevention, immunizing women during pregnancy to help provide protection for their babies immediately at birth and continuing up to 6 months, which is the — which is the period with the highest vulnerability for the infants. Seeing this innovative approach producing these results makes me again feel very proud. As we shared earlier in the year, at the recommendation of the independent data monitoring committee and in consultation with the FDA, we have stopped enrollment in our trial and plan to submit our BLA to the FDA by the end of the year. The Phase 3 data results demonstrate our vaccine candidate has a high level of efficacy, and the DMC indicated it was well tolerated with no safety concerns for either the vaccinated mothers or their infants. If approved, this will be the first investigational vaccine to help prevent RSV immediately at birth or better set from the first breath. At Pfizer, we are uniquely positioned to commercialize our vaccine candidate in both indications. We rely on our best-in-class commercial capabilities and decades of launch excellence that we have recently proven with our COVID-19 vaccine rollout and our Prevnar 20 adult launch in this indication. We have robust and differentiated contract model — contracting models, both with IDNs, the integrated delivery networks and with retailers. We also have proven reliable manufacturing supply and distribution capabilities and expertise in educating customers across various channels. As we look towards the commercial opportunity and the significant unmet need, we believe we have the potential to make a public health impact. Based on our Phase 3 interim analysis results in both potential indications, coupled with the unmet need, we project potential blockbuster revenues for our vaccine candidates. First, there are 2 distinct and big population groups that can benefit from this protection. Although the pregnant women population is relatively smaller, the burden of RSV is much better characterized with a clear need. Hence, we believe we can potentially reach a high uptake rate between 60% to 70%. As there are no other maternal immunization candidates in late-stage development, we anticipate 100% market share. If approved, we anticipate our data to support a favorable and year-round recommendation by ACIP. Monoclonal antibodies can be important complementary options, especially for babies who may need additional protection if they are approved. Let’s move to the older adult side. For older adults, the burden of the disease is less well known and often mistaken with flu and other causes of respiratory diseases. Despite this, we believe our vaccine can reach peak uptake rates of 50% to 60%. In this indication, we will have competition. But based on our vaccines clinical profile, our commercial capabilities and our anticipated launch timing, we believe we can potentially reach and sustain a market share between 45% to 60%. If approved, we anticipate our data to support a routine and age-based recommendation by ACIP. The key to success will be education. Educating everyone on the burden of the disease and on the favorable profile of our vaccine candidate, whether they are HCPs, providers, retailers, expecting mothers, older adults or caregivers. That will be the key to launch our investigational vaccine to address the significant unmet need and to reach our vaccine candidate’s potential which rolls up to be a potential multibillion dollar opportunity, again, if approved and recommended. Finally, our RSV vaccine candidate has the potential to strengthen our ever-growing respiratory portfolio of Prevnar franchise and COVID-19 franchise. Like with COVID-19, Pfizer’s commitment does not stop at the vaccine candidate, complementing our efforts to advance our RSV vaccine candidate, we also have Sisunatovir, an investigational therapeutic with the potential to help treat RSV-related illness. That is why we believe Pfizer is uniquely positioned to deliver successful launches and build upon our legacy as a leader in helping prevent and treat respiratory diseases. Thank you all for your attention. I would now like to hand it over to Kevin Sullivan, who leads our Specialty Care business globally, and who will provide details on Etrasimod and Ritlecitinib. 10 REFINITIV STREETEVENTS | http://www.refinitiv.com | Con
SearchHamburgerPfizer Signs Agreement to Provide the European Union with PAXLOVID™Wednesday, November 23, 2022 – 11:00amShare
• New agreement to supply up to 3.4 million treatment courses to countries across Europe; this deal supplements the courses provided to 17 EU member states under existing bilateral agreements • Deliveries to participating countries commencing imminently NEW YORK, November 23, 2022 — Pfizer Inc. (NYSE: PFE) today announced an agreement with the European Commission (EC) to supply its COVID-19 oral therapy, PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) to countries participating in the Joint Procurement Agreement across Europe. This agreement, negotiated with the Health Emergency Preparedness and Response Authority (HERA) of the EC, is in addition to the bilateral agreements Pfizer has previously signed with 17 EU Member States. This agreement will supply participating countries up to 3.4 million treatment courses upon orders being placed. Under the terms of the agreement, Pfizer will begin delivery of the initial treatment quantities ordered by the participating countries in November, in parallel to deliveries underway as part of existing bilateral agreements.“Clinical data and real-world evidence for PAXLOVID have shown that it can be an important tool in helping to reduce hospitalizations and deaths in those at increased risk of serious illness from COVID-19,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “As the region prepares for winter and a possible resurgence in COVID-19 infections, the accessibility and availability of treatment options is of the utmost importance. We are pleased to be working with the European Commission to make PAXLOVID available to more patients across Europe.”PAXLOVID is currently authorized for conditional or emergency use in more than 70 countries across the globe. Following the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) positive opinion to authorize PAXLOVID, a conditional marketing authorization (CMA) for PAXLOVID was granted in January 2022 for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming severe. Europe plays a critical role in the delivery of PAXLOVID to patients across the globe, as the site of four of Pfizer’s key PAXLOVID manufacturing facilities.About PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) PAXLOVID is a SARS-CoV-2 main protease (Mpro) inhibitor (also known as SARS-CoV-2 3CL protease inhibitor) therapy. It was developed to be administered orally so that it can be prescribed early after infection, potentially helping patients avoid severe illness (which can lead to hospitalization and death). Nirmatrelvir [PF-07321332], which originated in Pfizer laboratories, is designed to block the activity of the Mpro, an enzyme that the coronavirus needs to replicate. Co-administration with a low dose of ritonavir helps slow the metabolism, or breakdown, of nirmatrelvir in order for it to remain active in the body for longer periods of time at higher concentrations to help combat the virus.Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. PAXLOVID, however, works intracellularly by binding to the highly conserved Mpro (3CL protease) of the SARS-CoV-2 virus to inhibit viral replication. Nirmatrelvir has shown consistent in vitro antiviral activity against the following variants: Alpha, Beta, Delta, Gamma, Lambda, Mu, and Omicron BA.1, BA.2 and BA.4.PAXLOVID is generally administered at a dose of 300 mg (two 150 mg tablets) of nirmatrelvir with one 100 mg tablet of ritonavir, given twice-daily for five days. One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course.Our Commitment to Access Pfizer is committed to working toward equitable access to our oral COVID-19 treatment, PAXLOVID, for high-risk patients in need, aiming to deliver safe and effective oral treatment as soon as possible and at an affordable price. If authorized or approved, during the pandemic, Pfizer will offer its oral therapy through a tiered pricing approach based on the income level of each country to promote equity of access across the globe; high and upper-middle income countries will pay more than lower-income countries. Pfizer has established a comprehensive strategy in close partnership with worldwide governments, international global health leaders, including WHO’s Access to COVID-19 Tools Accelerator (ACT-A), and global manufacturers to optimize supply and access of PAXLOVID all around the world. This includes:
Multilateral Supply Agreements: Agreements in place with UNICEFfor the supply of up to 4 million treatment courses to 137 low- and middle-income countries and with Global Fund for up to 6 million treatment courses for supply to 132 Global-Fund grant-eligible countries, subject to regulatory approval or authorization.Expanding Access to Patent-Protected Medicines in Lower-Income Countries: Launched An Accord for a Healthier World, a first-of-its-kind initiative to enable sustained, equitable access to high-quality medicines and vaccines for 1.2 billion people living in lower-income countries. Pfizer has committed to provide its patent-protected medicines and vaccines available in the U.S. or European Union, including PAXLOVID, on a not-for-profit basis to 45 lower-income countries around the world and will collaborate with government and global health leaders to address barriers that limit access beyond supply, like diagnosis, education, infrastructure, storage and more.Accelerating Testing and Treatment: Joined the COVID Treatment Quick Start Consortium, a joint initiative implemented by Duke University, the Clinton Health Access Initiative (CHAI), COVID Collaborative and Americares with support from Pfizer, Open Society Foundations and the Conrad Hilton Foundation. Pfizer will provide treatment courses of PAXLOVID, as well as financial support, to support the Consortium’s efforts to accelerate COVID-19 testing and improve access to treatments in under-resourced parts of the world. The consortium has launched test and treat initiatives in partnership with ten countries in Africa and Southeast Asia. Humanitarian Treatment Donation: As part of its humanitarian response, Pfizer donated 200K treatment courses of PAXLOVID to Ukraine.Voluntary Licensing: Signed a voluntary license agreement with Medicines Patent Pool (MPP) to enable the development and distribution of generic versions of Pfizer’s oral treatment to further expand long-term global supply and access. MPP has signed sublicense agreements with 38 manufacturers, who will supply the generic versions in 95 low- and lower-middle-income countries.
U.S. FDA Emergency Use Authorization Statement PAXLOVID has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death. The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.AUTHORIZED USE The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PAXLOVID for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.LIMITATIONS OF AUTHORIZED USE
PAXLOVID is not authorized for initiation of treatment in patients requiring hospitalization due to severe or critical COVID-19PAXLOVID is not authorized for use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19PAXLOVID is not authorized for use for longer than 5 consecutive days
PAXLOVID may be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs.
PAXLOVID may also be prescribed for an individual patient by a state-licensed pharmacist under the following conditions:
Sufficient information is available, such as through access to health records less than 12 months old or consultation with a health care provider in an established provider‑patient relationship with the individual patient, to assess renal and hepatic function; and Sufficient information is available, such as through access to health records, patient reporting of medical history, or consultation with a health care provider in an established provider‑patient relationship with the individual patient, to obtain a comprehensive list of medications (prescribed and non-prescribed) that the patient is taking to assess for potential drug interaction.
The state-licensed pharmacist should refer an individual patient for clinical evaluation (e.g., telehealth, in-person visit) with a physician, advanced practice registered nurse, or physician assistant licensed or authorized under state law to prescribe drugs, if any of the following apply:
Sufficient information is not available to assess renal and hepatic function.Sufficient information is not available to assess for a potential drug interaction.Modification of other medications is needed due to a potential drug interaction.PAXLOVID is not an appropriate therapeutic option based on the authorized Fact Sheet for Healthcare Providers or due to potential drug interactions for which recommended monitoring would not be feasible.
PAXLOVID is not approved for any use, including for use for the treatment of COVID-19.
PAXLOVID is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PAXLOVID under 564(b)(1) of the Food Drug and Cosmetic Act unless the authorization is terminated or revoked sooner.IMPORTANT SAFETY INFORMATION PAXLOVID is contraindicated in patients with a history of clinically significant hypersensitivity reactions (eg, toxic epidermal necrolysis [TEN] or Stevens-Johnson syndrome) to its active ingredients (nirmatrelvir or ritonavir) or any other components of the product. Drugs listed in this section are a guide and not considered a comprehensive list of all drugs that may be contraindicated with PAXLOVID. The healthcare provider should consult other appropriate resources such as the prescribing information for the interacting drug for comprehensive information on dosing or monitoring with concomitant use of a strong CYP3A inhibitor such as ritonavir. PAXLOVID is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions:
PAXLOVID is contraindicated with drugs that are potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance. PAXLOVID cannot be started immediately after discontinuation of any of the following medications due to the delayed offset of the recently discontinued CYP3A inducer:
There are limited clinical data available for PAXLOVID. Serious and unexpected adverse events may occur that have not been previously reported with PAXLOVID use. Risk of Serious Adverse Reactions Due to Drug Interactions: Initiation of PAXLOVID, a CYP3A inhibitor, in patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving PAXLOVID, may increase plasma concentrations of medications metabolized by CYP3A. Initiation of medications that inhibit or induce CYP3A may increase or decrease concentrations of PAXLOVID, respectively. These interactions may lead to:
Clinically significant adverse reactions, potentially leading to severe, life-threatening, or fatal events from greater exposures of concomitant medicationsClinically significant adverse reactions from greater exposures of PAXLOVIDLoss of therapeutic effect of PAXLOVID and possible development of viral resistance
Consult Table 1 of the Fact Sheet for Healthcare Providers for clinically significant drug interactions, including contraindicated drugs. Drugs listed in Table 1 are a guide and not considered a comprehensive list of all possible drugs that may interact with PAXLOVID. Consider the potential for drug interactions prior to and during PAXLOVID therapy; review concomitant medications during PAXLOVID therapy and monitor for the adverse reactions associated with the concomitant medications.Anaphylaxis and other hypersensitivity reactions have been reported with PAXLOVID. Cases of Toxic Epidermal Necrolysis and Stevens-Johnson syndrome have been reported with ritonavir, a component of PAXLOVID (refer to NORVIR prescribing information). If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue PAXLOVID and initiate appropriate medications and/or supportive care.Hepatotoxicity: Hepatic transaminase elevations, clinical hepatitis, and jaundice have occurred in patients receiving ritonavir. Therefore, caution should be exercised when administering PAXLOVID to patients with pre-existing liver diseases, liver enzyme abnormalities, or hepatitis. Because nirmatrelvir is co-administered with ritonavir, there may be a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection.Adverse events in the PAXLOVID group (≥1%) that occurred at a greater frequency (≥5 subject difference) than in the placebo group were dysgeusia (6% and
The pandemic continued in Beijing and the death toll has increased sharply. Videos circulating on the internet showed a long line of vehicles transporting dead bodies to a crematorium in Beijing, but China’s Health Commission reported there were no new deaths after December 7. In addition, there are rumors that Beijing plans to send unvaccinated elderly people to field hospitals for treatment to address the shortage of medical resources.
According to NTD, on December 16, the Chinese media Caixin reported that two senior journalists of the People’s Daily newspaper died in Beijing after being infected with COVID-19, at the age of 74.
Although they died of COVID-19, the cause of death on the death certificate was pneumonia. (Photo)
The journal Nature Medicine estimates that within six months, China could trigger a new pandemic “tsunami.” As many as 112 million people will be infected, 2.7 million people will be admitted to the ICU, and 1.55 million people will die. Peak ICU demand will reach 1 million beds, more than 15.6 times the current capacity.
According to Sound of Hope, Zhang Fanghua (pen name), a Beijing resident, said that Beijing has released a large number of people from field hospitals and plans to use them for the unvaccinated elderly, just like Xiaotangshan hospital did during the SARS outbreak in Beijing in 2003.
She said that a person working at Xiaotangshan hospital told her, “Patients are provided with a bottle of mineral water every day, and buns or bread, not as good as you imagine. It’s not like that at all … You suffer on your own, you can come back if you are alive. Otherwise, you will get in the car (meaning will be a corpse). If you want to run away, maybe you will be beaten to death. These days, no one cares about you. It’s really terrible! Nationwide, 40% of the elderly are vaccinated, and 60% are not. So 60% of the elderly who are not vaccinated will be taken there.” (Recording)
On December 15, China’s National Medical and Health Commission issued a “Work plan to strengthen the control of the COVID-19 pandemic and health services in rural areas.” The commission proposes speeding up vaccinations in rural areas, especially the elderly, increasing the stock of ventilators and medicine in rural areas, and avoiding contact with the elderly. There are about 500 million people in rural China and there are about 17,000 county-level hospitals that are severely short of beds.
Zhang Wenhong, director of the Department of Infectious Diseases at Fudan University’s Huashan Hospital in Shanghai, recently predicted that it will take three to six months to overcome the pandemic, according to Sohu.
Tang Jingyuan, a political commentator, said: “The Chinese government has invested a large amount of health insurance funds including paying trillions of dollars to implement the ‘zero-COVID’ policy for three years, embarking on nationwide nucleic acid tests, building field hospitals everywhere, and hiring a large number of people to do quarantine work, implementing lockdowns and investigations. The but high quality vaccines and good drugs that are needed to fight the pandemic, including ICUs and ventilators, are in low supply. This is one of the most fundamental reasons leading to overcrowding and a lack of medical resources. This responsibility must certainly belong to the Chinese government.” (Recording 2)
80X More Deaths Following COVID-19 Shots than Influenza Vaccines 2020 through 2022
by Brian Shilhavy Editor, Health Impact News
An examination of the U.S. Government’s Vaccine Adverse Events Reporting System(VAERS) reveals that since the Fall of 2020 through today, people injected with COVID-19 shots die 80 times more frequently following those shots, than people who die after being injected with the flu shots.
Also, people receiving a COVID-19 shot suffer side effects 40 times more frequently than people who are injected with flu shots.
Here are the current stats in VAERS for people receiving a COVID-19 shot since they were issued an emergency use authorization in December of 2020. (Source.)
Here are the stats for the flu shots since September of 2020 (beginning of the “Flu season”.) (Source.)
To determine the rate of side effects and deaths suffered from these shots, we need the number of doses distributed for these time periods, and we find those numbers on the CDC website.
Total doses of COVID-19 shots distributed to date are 931,341,585. (Source.)
Total doses of flu shots distributed from September 2020 through December 10, 2022 are 527,610,000. Number of doses for the 2020-2021 and 2021-2022 flu seasons are found here, and total doses for the current 2022-2023 flu season through December 10, 2022 are found here.
Based on these numbers supplied by the U.S. Government, one person dies for every 2,284,026 flu shots, while one person dies for every 28,370 COVID-19 shots, which is a rate 80 times higher than the flu shots.
One person is suffering a side effect for every 25,217 flu shots, while one person is suffering a side effect for every 629 COVID-19 shots, which is a rate 40 times higher than the flu shots.
What is interesting about the CDC’s report on doses of COVID-19 shots distributed, is that even though 931,341,585 doses have been distributed, only 660,400,812 doses have been administered. So only 70% of the COVID-19 “vaccines” the U.S. Government has purchased have actually been injected into people. The other 30% presumably were discarded, or will be discarded after they reach their expiration date.
That of course makes the rate of people dying and suffering injuries following injections of COVID-19 shots even higher!
1 death per 20,117 shots
1 side effect per 446 shots
I do not know if statistics exist for the ratio of shots distributed to shots administered for the flu shots, which is why for comparison purposes we need to use the “shots distributed” statistics.
Governor DeSantis, Dr. Ladapo, and Other Florida Doctors are LYING About the Safety of Childhood Vaccines!
How about other vaccines that are approved by the FDA and part of the CDC childhood vaccination schedule?
At a recent event in Florida with Governor Ron DeSantis and his Surgeon General Joseph Ladapo, several other doctors sat a round table to discuss how COVID-19 shots were harmful and should NOT be recommended for children. See:
However, some of these doctors that sat at the table told parents to not stop injecting their children with other vaccines, and told them that these vaccines were “safe and effective.” One doctor, Dr. Joseph Friaman, even emphatically stated that other childhood vaccines had nearly no side effects. He said that they were rare, “1 in a million.”
Listen to their own words:
Let’s “fact check” this.
The U.S. National Vaccine Injury Compensation Program keeps stats on the number of doses distributed for all FDA-approved vaccines that are on the CDC childhood vaccination schedule. You can view those stats covering the time period of 01/01/2006 through 12/31/2021 at the U.S. Government website here.
During those years, there were over 4 billion doses of vaccines distributed (4,093,221,119).
Next, we can do a search in VAERS to see how many deaths and side effects were recorded from these vaccines during that same time period. The results are here.
During these years, there were 553,216 injuries and deaths recorded in VAERS from all non-COVID vaccines. That means a side effect from these vaccines was recorded in VAERS for about every 7,400 shots distributed.
That’s a lot more than 1 out of a million, as Dr. Friaman claimed! And of course the actual numbers are much HIGHER than this, because a report contracted out by the U.S. Government in 2011 found that less than 1% of all vaccine injuries are ever reported to VAERS. (Source.)
Here is the list of the vaccine manufacturers from VAERS that produced these vaccines that caused all these injuries and deaths, and each of these companies, especially the ones at the top of the list, have a criminal rap sheet where they have paid out $BILLIONS in criminal settlements.
So these doctors admit the COVID shots are bad, but they want you to trust them that all other vaccines, produced by the same corrupt companies, are somehow “safe”?
They can’t even prove these vaccines are effective! Dr. Bhattacharya mentioned the polio and MMR vaccines, and these are two of the biggest scams in the history of vaccines!
No child is dying in the U.S. today from measles, but many do die and are injured from the measles (MMR combo vaccine) vaccine.
All cases of polio today come from the vaccines. Please educate yourself on these non-COVID vaccines and the tremendous fraud surrounding them.
Here is an article I published earlier this year on the polio vaccine, and when you listen to Dr. Suzanne Humphries’ presentation on the history of the polio vaccine, you will see much of the same fraud we just observed with the COVID shots. The playbook doesn’t change much over the years.
Also, the CDC has refused over the years to study the health of children who follow the CDC childhood vaccination schedule and are fully vaccinated versus parents who choose not to vaccinate their children, and for good reason, because unvaccinated children are clearly much healthier. See:
Doctors find Graphene is shedding from the COVID Vaccinated to the Unvaccinated, forming Blood Clots & decimating Blood Cells
By The ExposéOctober 27, 2022
In his latest set of slides of blood samples taken from both “vaccinated” and unvaccinated people, Dr. Philippe van Welbergen demonstrated that the graphene being injected into people is organising and growing into larger fibres and structures, gaining magnetic properties or an electrical charge and the fibres are showing indications of more complex structures with striations.
He also demonstrated that “shards” of graphene are being transmitted from “vaccinated” to vaccine-free or unvaccinated people destroying their red blood cells and causing blood clots in the unvaccinated.
Let’s not lose touch…Your Government and Big Tech are actively trying to censor the information reported by The Exposé to serve their own needs. Subscribe now to make sure you receive the latest uncensored newsin your inbox…
Dr. Philippe van Welbergen (“Dr. Philippe”), Medical Director of Biomedical Clinics, was one of the first to warn the public of the damage being caused to people’s blood by Covid injections by releasing images last year of blood samples under the microscope.
At the beginning of July 2021, Dr. Philippe, was interviewed on a South African community channel, Loving Life TV. He explained that when his patients started complaining about chronic fatigue, dizziness, memory issues, even sometimes paralysis and late onset of heavy menstruation (women in their 60s upwards), he took blood samples. Their blood had unusual tube-like structures, some particles which lit up and many damaged cells. Few healthy cells were visible. Until three months earlier, he had never seen these formations in blood. We now know these tube-like structures are graphene.
Since then, Dr. Philippe has been a regular guest on Loving Life TV: blowing the whistle on the experimental Covid injection roll-out; providing updates on the increasing damage being done to blood by the experimental Covid injections over time; and, giving updates on the Covid situation in the UK and South Africa.
On 12 February 2022, Dr. Philippe returned again to Loving Life TV to release images of his latest slides of blood samples. The live stream was lengthy so Loving Life TV separated it into two parts.
Part One is a discussion including answers to the audience’s questions.
In Part Two, Dr. Philippe presents the images of his latest blood slides and explains what the images are showing. He discusses nearly 100 blood slides from both “vaccinated” and vaccine-free patients. His slides show that vaccine-free patients have been “infected with vaccine toxins through shedding.”
Below is a short clip from Part Two courtesy of The Timeline Post channel on Telegram.Dr Philippe (Part Two), The Blood Slides, 12 February 2022
Below is an image of typical healthy red blood cells as seen with a microscope, what blood should look like. There is no coagulation or foreign objects in it.
The next image is of a person who has been injected with the experimental Covid drug. The blood is coagulated, the misshapen red blood cells are clumped together. The cell encircled in the image is a healthy red blood cell, one of the few in the image, sitting alongside the graphene fibres. You can see the size of the graphene fibres in relation to the size of a red blood cell. Fibres of this size will block capillaries. You can also see the graphene fibres are hollow and contain red blood cells.
A couple of weeks before the video below was made, Dr. Philippe began noticing a magnetic or electrical polarity effect on different sides of the graphene fibres. In the image below, to the right of the fibre the cells are coagulated and on the left-hand side is what looks like a gap or roughly backwards “C” shaped spacing. Dr. Philippe says that this “behaviour” was not seen before but now, all of a sudden, it is being seen in almost every sample. It is an indication that “these things have changed, their reaction with surrounding blood cells has changed … and I don’t know what triggered it,” he said.
The image below is of a blood sample from a vaccine-free, or unvaccinated, three-year-old child. It shows pieces or “shards” of graphene that “are the result of shedding,” in other words the graphene has been transmitted from “vaccinated” parents to their unvaccinated child.
Below is the image of a blood sample from an eight-year-old unvaccinated child whose blood has been contaminated and destroyed by the transmission of graphene from those around him/her who have had a Covid injection. The child’s right arm and upper right leg are basically paralysed, the child is unable to lift his/her right arm and the thigh is not functioning properly.
Dr. Philippe’s presentation is truly eye opening and horrifying – a must watch, especially for those who proclaim Covid injections are “safe” and are insisting people be injected. The Covid injections are weapons of genocide and how the people who have designed them are still walking free is incredible.
You can either watch the presentation below or on Loving Life TVHERE.Loving Life TV: Dr Philippe (Part Two), The Blood Slides, 12 February 2022 (90 mins)
LONDON – A new U.K. study indicates the Pfizer Inc./Biontech SE COVID-19 vaccine is less effective against the India variant of the SARS-CoV-2 virus that was designated as of global concern by the World Health Organization (WHO) on May 10.
Blood samples taken from healthy volunteers at different time points after receiving one or two doses of the Pfizer vaccine had lower levels of neutralizing antibodies against the India variant than against the Kent and South Africa variants of concern.
In people who were fully vaccinated with two doses of the Pfizer vaccine, titers of neutralizing antibodies against the India variant were 5.8-fold lower than against the original Wuhan virus against which the Pfizer vaccine was designed.
That compares to a 2.6-fold reduction vs. wild type for the Kent variant, and 4.9-fold for the variant originally identified in South Africa.
The antibody response against the India variant was even lower after a single dose, with only 32% of serum samples showing a quantifiable neutralizing antibody response, compared to 79% for the wild type.
Levels of neutralizing antibodies were lower with increasing age and levels decline over time, suggesting that third, booster doses of vaccine will be needed later in the year.
The samples in the study came from 250 health care workers and staff at University College London and its associated hospital who have been making regular blood donations.
In total, 308 samples from different time points were tested with a new high-throughput viral neutralization assay developed at the Francis Crick Institute, London. The times ranged from 23 days after a first dose to 37 days after a second.
The high-throughput assay allowed serum to be tested against live samples of each virus variant in a single experiment, enabling direct comparison of neutralizing antibody titers.
The study, reported in The Lancet, relates only to Pfizer’s vaccine, but the researchers are now doing the same assessment for Astrazeneca plc’s COVID-19 vaccine.
Decline over time
A further study in a subgroup of 14 participants who donated blood between eight and 12 weeks after their second dose of the Pfizer vaccine also showed significantly reduced neutralizing antibody activity against all variants of concern. For 12 of those individuals, the reaction was high enough to block 50% of virus infection, but for two participants activity against the India and South Africa variants dropped below 40%.
The researchers said their findings raise the question of whether the U.K. should maintain its policy of administering two vaccine doses 12 weeks apart. That was shown to be the correct strategy at the start of the vaccination rollout, providing some level of protection to as many people as possible when vaccine supplies were limited.
With the data showing that after a single dose of vaccine neutralizing antibodies against the India and South Africa variants are below the quantitative limit of detection, extended dosing intervals may no longer be appropriate.
The India variant has now replaced its Kent counterpart as the dominant cause of infection in the U.K. Despite relatively high levels of vaccine coverage, with 50% of the adult population having received two doses and 75% one dose, the number of infections has started to rise again, and some experts saying this could be the start of a third wave.
The seven-day average was 3,853 cases per day in the week up to June 2; on June 3, 5,274 cases were reported; on June 4, 6,238. The number of PCR-confirmed cases per day is still low compared to the height of the second wave in March this year, but the India variant is showing signs of being more transmissible than the Kent variant.
There also has been an increase in hospital admissions in areas of the country where case levels are higher.
Taken together, the neutralizing antibody levels and the epidemiological data raise the possibility that the India variant presents a dual challenge of reduced vaccine efficiency and greater transmissibility. “It remains difficult to assess precisely to what extent the reduction in [neutralizing antibody titers] we observe will impact vaccine efficacy and increase disease severity in a vaccinated population, especially given the multiple factors that contribute to this process, such as long live humoral immunity,” the researchers said.
A single dose still provides more protection than no vaccination, but will give relatively less protection against the India variant. “The benefits of delaying the second dose must now be weighed against decreased efficacy in the short term, in the context of the spread of the India variant,” said the researchers.
The most important thing will be to ensure vaccine protection remains high enough to keep as many people out of the hospital as possible, said Emma Wall, consultant in infectious diseases, who is clinical lead for the study.
“Our results suggest the best way to do this is to quickly deliver second doses and provide boosters to those whose immunity may not be high enough against these new variants,” Wall said.
What’s in a name?
In other news, WHO has come up with a new naming system for key variants of SARS-CoV-2 that it said are easier to say and remember, using the Greek alphabet.
The Kent variant has become Alpha, South Africa is Beta, the Brazil variant Gamma and the Indian variant Delta. The labels do not replace the existing scientific names, such a B.1.1.7 for the Kent variant, which convey important scientific information.
But WHO said these scientific names can be difficult to say and recall. As a result, the default is to refer to variants by the places where they are first detected. That is “stigmatizing and discriminatory,” WHO said.
It may take time for the nomenclature to shift. The default since WHO announced the new names has been to use all three alternatives: B1.1.7, the Kent variant, now known as Alpha.